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Abstract
Background: Observational cohort studies have suggested that minimally invasive distal pancreatectomy (MIDP) is
associated with better short-term outcomes compared with open distal pancreatectomy (ODP), such as less
intraoperative blood loss, lower morbidity, shorter length of hospital stay, and reduced total costs. Confounding by
indication has probably influenced these findings, given that case-matched studies failed to confirm the superiority
of MIDP. This accentuates the need for multicenter randomized controlled trials, which are currently lacking. We
hypothesize that time to functional recovery is shorter after MIDP compared with ODP even in an enhanced
recovery setting.
Methods: LEOPARD is a randomized controlled, parallel-group, patient-blinded, multicenter, superiority trial in all 17
centers of the Dutch Pancreatic Cancer Group. A total of 102 patients with symptomatic benign, premalignant or
malignant disease will be randomly allocated to undergo MIDP or ODP in an enhanced recovery setting. The
primary outcome is time (days) to functional recovery, defined as all of the following: independently mobile at the
preoperative level, sufficient pain control with oral medication alone, ability to maintain sufficient (i.e. >50%) daily
required caloric intake, no intravenous fluid administration and no signs of infection. Secondary outcomes are
operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life and costs.
Discussion: The LEOPARD trial is designed to investigate whether MIDP reduces the time to functional recovery
compared with ODP in an enhanced recovery setting.
Trial registration: Dutch Trial Register, NTR5188. Registered on 9 April 2015
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Background
Minimally invasive surgery, which includes both laparo-
scopic and robot-assisted surgery, has undoubtedly been
one of the most significant advances in surgery during
the past decade and is now the preferred approach for
many surgical procedures [1–8]. Minimally invasive sur-
gery aims to reduce postoperative pain and complica-
tions and shorten the time to functional recovery [1–8].
Minimally invasive distal pancreatectomy (MIDP) was
first described in 1994 by Cuschieri et al. [9] Since then,
several observational cohort studies from expert centers
have suggested that MIDP is safe, feasible and cost-
effective in the treatment of benign, premalignant and
malignant lesions of the distal pancreas [10, 11]. These
suggestions were confirmed by several systematic
reviews of cohort studies that reported reductions in
intraoperative blood loss, blood transfusion, complica-
tions, wound infections and shorter hospital stay, and an
increased rate of spleen preservation, all in favor of the
minimally invasive approach [10, 11].
Regarding oncologic parameters, including resection
margins and lymph node retrieval, the minimally
invasive approach is considered to be at least non-
inferior to conventional open distal pancreatectomy
(ODP) [12–15]. Case-matched studies, however, have
not confirmed the presumed benefits of MIDP [10], indi-
cating that confounding by indication has clearly played
a role in the reported results in cohort studies. This is
confirmed by a difference in baseline characteristics as
reported in many series, such as smaller tumor size in
the MIDP group [11]. It is therefore currently unknown
whether MIDP, as a routine strategy, actually offers clin-
ically relevant advantages over ODP. Most cohort series
were performed in high-volume expert centers, so it is
uncertain whether these outcomes of MIDP are
generalizable [10]. Hence, randomized controlled trials
are needed in order to provide high-quality evidence on
the benefits of MIDP over ODP.
Minimally invasive approaches are often assumed to
be more expensive than open surgery, because of the
need for expensive surgical equipment and sometimes
prolonged operative times. However, for several proce-
dures, such as appendectomy, cholecystectomy and col-
ectomy, no difference in overall costs has been
demonstrated, mainly because reduced hospital stay bal-
anced the higher procedural costs [16]. The current lit-
erature is unclear as to the cost difference between
MIDP and ODP [10].
In 2014, the Dutch Pancreatic Cancer Group (DPCG)
initiated the longitudinal assessment and realization
of minimally invasive pancreatic surgery in The
Netherlands (LAELAPS) training program to imple-
ment minimally invasive pancreatic surgery in The
Netherlands [17]. This program follows the preferred
steps of surgical innovation according to the innovation,
development, exploration, assessment and long-term
study (IDEAL) statement [18–20].
First, a nationwide retrospective analysis on distal pan-
createctomy was performed in order to assess the
utilization and outcomes of MIDP and ODP [21]. In this
retrospective multicenter study in 633 patients, MIDP
appeared to be at least non-inferior to ODP, but the na-
tionwide underuse of MIDP (10%) and high conversion
rate (38%) revealed clear room for improvement. The
subsequent nationwide LAELAPS training program in-
cluded detailed technique standardization and descrip-
tion, video training and proctoring [17]. In the period
after training, there was a sevenfold increase in the use
of MIDP, and blood loss and conversion rates decreased
even during surgery on more complex tumors, including
more pancreatic ductal adenocarcinomas. The 8% con-
version rate, 17% Clavien-Dindo grade III or higher
complication rate, 6 days hospital stay and 0% 30-day
mortality in the period after training were comparable to
results from expert centers in the UK and USA [11].
According to the IDEAL framework, a randomized con-
trolled trial should be the next step [18–20]. Accord-
ingly, the aim of the LEOPARD trial is to compare the
outcomes, including time to functional recovery, compli-
cations, quality of life and costs, after MIDP with ODP
within an enhanced recovery setting.
Methods
Design
The LEOPARD trial is a randomized controlled, parallel-
group, patient-blinded, multicenter, superiority trial in-
vestigating the effectiveness of MIDP versus ODP for
treatment of symptomatic benign, premalignant or ma-
lignant disease of the distal pancreas in an enhanced re-
covery setting. Eligible patients will be randomized
equally to either MIDP or ODP. Splenectomy will be
performed only when indicated for oncological or tech-
nical reasons.
Trial population
All adult patients with an indication for elective distal
pancreatectomy (with or without splenectomy) because
of suspected or proven symptomatic benign, premalig-
nant or malignant disease of the distal pancreas, from 17
centers performing pancreatic surgery in The Netherlands
will be assessed for eligibility.
Inclusion criteria
The inclusion criteria are as follows:
 Age equal to or above 18 years
 Indication for elective distal pancreatectomy
(with or without splenectomy) because of proven
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or suspected left-sided symptomatic benign,
premalignant or malignant disease
 Tumor meeting the Yonsei criteria [22]
(tumor or cyst confined to the pancreas with
an intact posterior pancreatic fascial layer
and the tumor located at least 1 cm from the
celiac axis)
 Sufficiently fit to undergo distal pancreatectomy
according to the surgeon and anesthetist
Exclusion criteria
The exclusion criteria are as follows:
 Tumor or cyst larger than 8 cm
 Surgical intervention (resection or ablation) of other
organs besides the distal pancreas or spleen are
required (cholecystectomy is allowed)
 Previous radiotherapy as treatment of pancreatic
cancer
 Chronic pancreatitis (according to the M-ANNHEIM
criteria)
 Pregnancy
 Participation in another study with interference in
study outcomes
Randomization
Patients will be randomized centrally by the trial coordi-
nators using an online randomization module (ALEA,
Clinical Research Unit, Academic Medical Center,
Amsterdam, The Netherlands) in a 1:1 ratio between
MIDP and ODP, as shown in Fig. 1. Randomization will
be stratified by center to balance differences in the
surgical procedure and general treatment regimens
and by the indication for surgery (malignant versus
Fig. 1 Minimally invasive versus open distal pancreatectomy for symptomatic benign, premalignant and malignant disease (LEOPARD) trial flow
diagram according to standard protocol items: recommendations for interventional trials (SPIRIT) [45]. IC informed consent, DP distal
pancreatectomy, EQ-5D-5 L Euro-QoL five health dimensions questionnaire, QLQ-C30 quality of life questionnaire including 30 questions
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non-malignant disease). Permuted-block randomization
will be used to provide treatment allocation in equal pro-
portions, with block sizes that will be subject to random
variation. This will be concealed to all investigators in-
volved in the trial.
Intervention: minimally invasive distal pancreatectomy
Patients are under general anesthesia for minimally inva-
sive distal pancreatectomy, and epidural anesthetic is
not mandatory. The patient is placed in a supine pos-
ition, left side 30 degrees elevated with legs apart. In
total, four to five (2 × 12 mm and 2 × 5 mm to 3 ×
5 mm) trocars are placed in a semicircular fashion, cen-
tered around the supra-umbilical camera. The surgeon
stands at the patient’s right side, the assistant controlling
the camera stands between the patient’s legs and the as-
sistant surgeon stands at the patient’s left side.
The omental bursa is opened by dividing the gastro-
colic ligament using an ultrasonic device (Harmonic
ACE® + 7 Shears, Ethicon Inc., Cincinnati, OH, USA), or
standard of care. Division of the short gastric arteries de-
pends on the indication of spleen preservation. In
patients with spleen-preserving surgery, the left gastro-
epiploic artery and short gastric vessels are fully pre-
served. The posterior fundus of the stomach is retracted.
The lesion is identified, either visually or with laparo-
scopic ultrasound. The splenic artery is identified at the
superior margin of the pancreas and slung with a vessel
loop which is secured with a Hem-o-lok® clip (Teleflex
Medical, Weck Drive, Research Triangle Park, NC,
USA). Optionally, in spleen-preserving surgery, a laparo-
scopic bulldog clamp can be placed on the artery to
reduce blood loss during the procedure. Transection is
postponed until the anatomy (especially the hepatic ar-
tery and celiac trunk) is confirmed. Alternatively, the
stomach is retracted caudally and the common hepatic
artery, celiac trunk and splenic artery are identified cra-
nial to the stomach.
The caudal margin of the pancreas is mobilized and
the inferior and superior mesenteric veins are identified.
An umbilical tape is placed under the pancreas between
the lesion and the spleen and secured with a Hem-o-lok®
clip. In the case of suspected malignancy this umbilical
tape includes Gerota’s fascia as described previously [23].
The same procedure is performed at the right side of the
tumor, potentially over the portomesenteric vein. In the
case of malignancy, lymphadenectomy is performed ac-
cording to the International Study Group on Pancreatic
Surgery (ISGPS) consensus [24]. If the tumor is localized
in the pancreatic body, lymphadenectomy also involves
station 9 (around the celiac trunk).
Dissection according to the radical antegrade modular
pancreatosplenectomy (RAMPS) method, as described
by Strasberg [25], which includes lymph node dissection
from the common hepatic artery to the celiac trunk and
splenic artery, is advised in the case of malignancy. The
left gastric artery is preserved if possible. In the case of
benign and premalignant lesions attempts are made to
preserve the spleen. These vessels are either completely
spared (Kimura’s technique [26]) or if complete preser-
vation of the splenic vessels is not feasible they will be
divided using either Hem-o-lok® clips (at least two clips
on the patient’s side) or stapling devices, so the spleen
only receives blood via the short gastric arteries
(Warshaw’s technique [27]). Splenectomy is performed
in the case of gross splenic ischemia. Splenectomy is
routinely performed in the case of malignant lesions or
risk of malignancy.
The pancreas is divided using an endostapler with the
staple cartridge size adapted to the thickness of the pan-
creas. A graded progressive compression technique is
used as described by Asbun et al. [28]. Additional sutur-
ing of the pancreatic stump, covering the stump with
tissue or a patch, or staple-line reinforcement is allowed.
A medial-to-lateral approach is used during the
mobilization of the pancreas. The pancreatic tail (with
or without the spleen) is put into a leak-proof retrieval
bag and extracted using a Pfannenstiel incision or an en-
larged trocar incision. A surgical drain is placed near the
pancreatic remnant. In the case of splenectomy this
drain is placed via a long loop through the left upper
quadrant with additional side holes to drain the splenic
bed. The same approach can be followed with the
DaVinci® console. Small variations according to the sur-
geon’s preference are allowed, but have to be recorded in
the case report form.
Control: open distal pancreatectomy
Patients undergo multimodal pain therapy with either an
epidural catheter or wound catheters with patient-
controlled analgesia [29]. Subcostal or midline laparot-
omy is performed. The steps taken are essentially similar
to minimally invasive surgery but variation in technique
is expected to be larger. In the case of benign or prema-
lignant disease an attempt at splenic preservation is
made, preferably using Kimura’s technique [26] (preser-
vation of splenic vessels), but otherwise using Warshaw’s
technique [27] (transecting splenic vessels). Tissue dis-
section during ODP, except for pancreatic transection,
will be performed using a standardized ultrasonic device
(Harmonic ACE® + 7 Shears, Ethicon Inc., Cincinnati,
OH, USA, or similar device) within the LEOPARD trial.
The pancreas is transected with a stapler. Alternatively,
transection with ultrasonic devices, diathermia or sharp
transection with suturing is allowed, as it is not expected
that this will influence perioperative outcomes [30].
Additional suturing of the pancreatic stump, covering
the stump with tissue or a patch, or staple-line
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reinforcement is allowed. Small variations according to
the surgeon’s preference are allowed, but have to be re-
corded in the case report form.
Conversion from MIDP to ODP
Conversion is defined as any MIDP (laparoscopic or
robot-assisted) in which an incision is used for reasons
other than trocar placement or specimen extraction. Pa-
tients allocated to MIDP who undergo intraoperative
conversion to ODP will still be analyzed in the MIDP
group according to intention-to-treat principles. Reasons
for conversion will be registered.
Patient blinding
Patients will be blinded using a large (30 × 30 cm) ab-
dominal dressing, which is administered in the operating
room immediately after the operation (Fig. 2). Patients
are blinded until functional recovery has been reached
or at least up to day 5 postoperatively. Earlier removal of
the dressing is allowed for urgent medical reasons. Previ-
ous trials in The Netherlands have found this approach
feasible [8, 31]. Full blinding of medical and nursing
ward staff would include masking surgical notes to the
hospital electronic patient system and is not considered
feasible in all 17 centers.
General treatment regimen
Postoperative care is similar in both arms and based on
enhanced recovery after surgery principles, which in-
clude early mobilization and expanding oral intake as
desired by the patient. When patients are functionally
recovered, they are essentially medically ready to be dis-
charged. The final date of discharge will be determined
by the local treating team.
Primary outcome
The primary outcome is time to functional recovery
(days). Functional recovery will be daily assessed by the
nurses, ward physicians and the trial coordinators and is
reached when all of the following criteria are met:
 Adequate pain control with oral analgesia only
 Restoration of mobility to an independent level
(or to preoperative level if previously impaired)
 Ability to maintain sufficient caloric intake
(minimum of 50% required calories); absence of
intravenous fluid administration
 No signs of active abdominal infection (in the case
of abdominal infection this item is met when serum
C-reactive protein is below 150 mg/L and the
patient has no fever)
Secondary outcomes
The secondary outcomes of this trial include operative
outcomes (type of approach, vascular tumor involve-
ment, tumor involvement in multiple organs, type of
primary and secondary surgeon (resident, fellow or sur-
gical specialist), conversion and reason for conversion,
method of pancreatic transection, spleen preservation
(including technique: Kimura/Warshaw), vessel resec-
tion, intraoperative blood transfusion, administration of
somatostatin analogs, intra-operative complications, op-
erative time (from first incision to full skin closure), total
duration of the procedure and intraoperative blood loss,
type of analgesia), postoperative outcomes (pain man-
agement, complications (e.g. postoperative pancreatic
fistula, post-pancreatectomy hemorrhage, delayed gastric
emptying and surgical site infection), postoperative
intervention (radiologic, endoscopic, surgical), postoper-
ative blood transfusion, intensive care unit admission,
length of hospital stay, readmission, time to start adju-
vant chemotherapy (in the case of malignant disease),
mortality and Clavien-Dindo scores of all individual
complications), pathology parameters (resected specimen
length, tumor size, histopathological diagnosis, resection
margins (including transection, anterior circumferential
Fig. 2 Abdominal dressing used to blind the patient for the type of
distal pancreatectomy
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and posterior circumferential margins, in the case of
malignancy), lymph node retrieval, tumor-positive lymph
node retrieval (in the case of malignancy), neural and vas-
cular tumor invasion), costs (intra-operative and postoper-
ative costs) and quality of life.
Data collection and patient follow up
Baseline data (on age, sex, performance status (Karnofsky
score), American Society of Anesthesiologists physical sta-
tus, body mass index, malnutrition universal screening
tool score (MUST), ERAS mobility scale [31, 32], diabetes
mellitus, previous abdominal surgery, preoperative
imaging including tumor size and involvement of
other organs, preoperative diagnosis, indication for
hospitalization, indication for surgery) will be col-
lected before randomization using standardized case
report forms. Data on the primary and secondary out-
comes will be collected from randomization up to
90 days postoperatively, by the local treating physi-
cians or the trial coordinators using standardized case
report forms. The case report forms and the database
will be crosschecked with source data by the trial
coordinators.
Patients will be asked to complete validated question-
naires (EQ-5D-5 L and QLQ-C30) at 2 weeks, 4 weeks
and 12 weeks postoperatively (Fig. 1). One year after sur-
gery, patients will be asked whether they are totally
recovered and will be asked to complete questionnaires
on quality of life (Euro-QoL 5 health dimensions ques-
tionnaire (EQ-5D-5 L) and Quality of life questionnaire
including 30 questions (QLQ-C30)), complications and
whether they would recommend MIDP or ODP to a
friend or family member. Long-term follow-up results of
the LEOPARD trial (including complications and quality
of life) will be published separately.
Definitions
The distal pancreas is defined as the proportion of the
pancreas located at the left of the portomesenteric vein.
Complications are classified using the Clavien-Dindo
score [33]. Major complications are defined as a
Clavien-Dindo score III or higher. Postoperative pancre-
atic fistula [34], delayed gastric emptying [35] and post-
pancreatectomy hemorrhage [36] are classified using the
International Study Group on Pancreatic Fistula (ISGPF)
and the International Study Group on Pancreatic
Surgery (ISGPS) definitions, respectively. Surgical site in-
fection is classified according to the Centers for Disease
Control and Prevention definition [37]. In the case of
malignant pancreatic disease, resection margins, includ-
ing transection and circumferential margins, are classi-
fied by a margin to tumor distance ≥1 mm (R0), a
margin to tumor distance <1 mm (R1) or a macroscopic-
ally positive margin (R2) [38]. Tumor, node, metastases
(TNM) status is classified according to the American
Joint Committee on Cancer (AJCC) classification (7th
edition).
Quality and safety
Surgeons will only be allowed to participate in the
LEOPARD trial when they have completed LAELAPS
training in MIDP [17] and have performed >50 advanced
minimally invasive advanced gastrointestinal procedures,
>20 distal pancreatectomies (either MIDP or ODP) and
>5 MIDPs. An advanced minimally invasive gastrointes-
tinal procedure is defined as any minimally invasive
gastrointestinal procedure beyond diagnostic laparos-
copy, cholecystectomy and appendectomy. If surgeons
do not meet all of the predefined criteria, they will be
assisted by an experienced MIDP surgeon (defined as
having performed >20 MIDPs) as often as necessary
until the criteria are met. Each participating surgeon will
record a video of the first MIDP performed in the trial.
This video will be shortened to enable efficient scoring
of the operator’s skills and scored by an expert MIDP
surgeon, who will score the video (blinded for the sur-
geon and clinical outcomes) using the method described
by Birkmeyer et al. [39]. The expert surgeon will assess
each video in five domains of technical skills (gentleness,
tissue exposure, instrument handling, time and motion
and flow of the operation). Each domain will be rated
on a scale of 1–5, where 1 indicates the skill expected
of a general surgical resident and 5 the skill of a mas-
ter surgeon in the procedure of minimally invasive
distal pancreatectomy.
All adverse events reported spontaneously by the
patient or observed by the investigator or his staff
will be recorded up to 90 days postoperatively. Ser-
ious adverse events occurring within 90 days after
treatment will be recorded. Only serious adverse
events from a predefined list will be reported through
a Web portal to the central committee on research
involving human subjects (in Dutch: central Commissie
Mensgebonden Onderzoek) and the accredited institutional
review board (www.toetsingonline.nl). This includes ser-
ious adverse events that necessitate intensive care unit ad-
mission, necessitate surgical intervention, necessitate
readmission or result in mortality (for any reason). The
remaining events are recorded in a yearly overview list.
An independent data safety monitoring board will meet to
investigate the safety parameters after every 25 included
patients. This data safety monitoring board comprises one
independent statistician/epidemiologist (Chair), one inde-
pendent gastroenterologist and one independent surgeon.
The result(s) of the data safety monitoring board meeting
will be sent to all participating physicians involved in this
trial. Furthermore, the result of the meeting will be relayed
to the trial steering committee. The advice of the data
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safety monitoring board will only be sent to the sponsor
of the trial.
Statistical aspects
Sample size calculation
The LEOPARD trial is designed as a superiority trial, hy-
pothesizing that the time to functional recovery is sig-
nificantly shorter after MIDP compared with ODP.
Based on the most recently published meta-analysis [11]
and Dutch nationwide data, a time to functional recov-
ery of 8 days in the control group (ODP) versus 6 days
in the intervention group (MIDP) is expected with a
standard deviation of 3 days. The significance level (α) is
set at 0.05 and power (1-β) at 80%. The sample size
needed in each arm, calculated using the independent
samples t test, is 36 patients. Including 15% crossover
from the MIDP to ODP and a rate of 2% loss to follow
up (based on previous studies), a total of 51 patients will
be randomized in each group, so a total of 102 patients
will be randomized in the LEOPARD trial.
After completion of data collection in the first 75 pa-
tients, the data safety monitoring board will assess po-
tential data skewness and homogeneity of variance for
time to functional recovery. When a non-parametric test
seems indicated for the comparison of MIDP versus
ODP on time to functional recovery, the total sample
size will become the calculated sample size (102) divided
by the asymptomatic relative efficiency parameter of the
Mann–Whitney U test (0.955). In that case, a total of
108 patients will be randomized in the LEOPARD trial.
Procedures performed using the robot DaVinci® Surgical
System are allowed in this trial, but will be analyzed sep-
arately during the cost analysis.
Statistical analysis
Primary and secondary outcomes will be crosschecked
with data from primary sources and a blinded adjudica-
tion committee will check them against the definitions,
which were established before the start of this trial. Cat-
egorical variables will be compared using the chi-square
or Fisher’s exact test as appropriate, and values will be
expressed as proportions. The distribution of continuous
variables will be determined using visual inspection and
the Kolmogorov-Smirnov test.
For comparison of normally distributed continuous
variables the independent samples t test will be used and
values will be expressed as means with standard devia-
tions. Continuous non-normally distributed variables
will be compared using the Mann–Whitney U test and
values will be expressed as medians with interquartile
ranges. Measures of association will be expressed as rela-
tive risks with 95% confidence intervals. A difference
with a two-tailed P-value <0.05 will be considered statis-
tically significant.
Analyses will be performed based on intention-to-treat
principles, meaning that converted MIDP will be
assessed in the MIDP group. A multivariable linear re-
gression model will be used to assess potential differ-
ences between groups in the primary outcome in the
presence of potentially confounding factors. Linear
mixed modeling will be applied to estimate differences
between groups in successive EQ-5D-5 L and QLQ-C30
assessments over time. For exploratory purposes a sec-
ondary analysis will be performed comparing outcomes
in patients with malignant versus non-malignant disease,
comparing completed MIDP (i.e. no conversion) versus
ODP and comparing time to functional recovery be-
tween MIDP and ODP in patients with complications
(Clavien-Dindo score ≥ III) and without complications.
Dissemination policy
The results of the LEOPARD trial will be submitted to a
peer-reviewed journal regardless of the outcome.
Authorship will be based on international guidelines.
Participants who do not fulfil the authorship criteria will
be listed in PubMed as ‘collaborators’.
Discussion
The LEOPARD trial is a multicenter randomized con-
trolled trial designed to assess whether MIDP reduces
the time to functional recovery compared with ODP, in
an enhanced recovery setting. LEOPARD was initiated
by the Dutch Pancreatic Cancer Group, a national collab-
oration of surgeons, gastroenterologists, medical oncolo-
gists, pathologists, (interventional) radiologists, dietitians
and nurses, which aims to improve the treatment of be-
nign, premalignant and malignant pancreatic disease.
The LEOPARD trial is the first multicenter random-
ized controlled trial comparing MIDP to ODP. On the
World Health Organization trial registry website, incorp-
orating all (inter)national trial registries, there are only
two single-center randomized trials reported in this field.
The first trial (LAPOP) with a total sample size of 60 pa-
tients is from Sweden and is planned to be completed in
2020 [40]. Patients are not blinded to the intervention in
this trial. The second trial is from the USA and was
never started [41]. Randomization is essential to exclude
the strong influence of selection bias. The LEOPARD
trial is expected to be the first multicenter randomized
trial to report high-level evidence, which will be of
significant value for clinical practice and guideline devel-
opment. Furthermore, this project will not only corrob-
orate the demonstrated advances in reducing hospital
stay and morbidity, but will also generate evidence on
quality of life and costs. Several recently published studies
have suggested that the generalizability of the benefits of
MIDP remains undefined and randomized controlled
multicenter trials are therefore needed [10–12].
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There is no obvious clinical diversity in patients diag-
nosed with left-sided pancreatic disease, as these lesions
are found in both women and men, at all ages, with dif-
ferent ethnicity. All of these demographic diversities, ex-
cept for children, will be fully represented in the
LEOPARD trial and the investigated procedures are uni-
form for all patients. The LEOPARD trial hypothesizes a
superior value of MIDP for time to functional recovery
and therefore all indications for elective distal pancrea-
tectomy (with or without splenectomy) can be included.
The Yonsei criteria will ensure oncological safety in pa-
tients diagnosed with pancreatic cancer within this trial,
as it increases the probability of achieving R0 tumor
resection margins [22]. Additional analyses will be per-
formed to investigate the outcomes in several subgroups
of patients (e.g. those with non-malignant versus malig-
nant disease and those with and without complications).
Within the LEOPARD trial, laparoscopic surgery and
robot-assisted surgery are both considered minimally in-
vasive and therefore both are allowed in the “minimally
invasive” arm. Furthermore, no clear differences in hos-
pital stay and morbidity have been shown for one versus
the other [10].
Patient blinding should be performed (if possible) in
randomized controlled trials to decrease the influence of
several types of bias and should especially be considered
in trials with patient-reported outcome measures as the
primary and/or secondary outcome [42]. Functional re-
covery is partly patient-reported (e.g. pain perception)
and is easily influenced by the patient’s expectation.
Patient blinding is therefore essential to eliminate the
Hawthorne effect, which means that if patients know
that they have been allocated to a specific arm, their be-
havior and response will consequently be influenced
[43]. Patient blinding in randomized controlled trials in
abdominal surgery has been successfully performed in
previous trials [8, 31], but its impact remains to be
assessed [44].
In conclusion, the LEOPARD trial is a multicenter ran-
domized controlled trial investigating time to functional
recovery after MIDP versus ODP. This trial aims to
provide level-1 evidence on the added value of the min-
imally invasive approach. When this hypothesis is con-
firmed, it will enhance the worldwide implementation of
MIDP and consequently improve patient outcomes.
Trial status
The first patient was randomized on 9 April 2015. At
the time of protocol submission (9 November 2016), all
centers were actively recruiting patients for the trial and
78 of 102 patients (76%) have been randomized, which
means that recruitment is on schedule.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 112 kb)
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